EQT Takes $2B McGill Stake From Warburg as Specialty Brokerage Cycle Turns

EQT acquired a majority position in McGill and Partners from Warburg Pincus at a $2 billion enterprise valuation, the second large specialty brokerage secondary this month. The London-based firm, founded in 2020 by former Jardine Lloyd Thompson executives, writes placements in aviation, financial lines, and marine hull—coverage categories where rate adequacy remains contested and capacity is consolidating. Warburg entered at inception four years ago. EQT's entry price implies a trailing EBITDA multiple in the low twenties, assuming McGill's reported $90-100 million run-rate from last year held through this quarter.

The deal closes the same week KKR sold USI Insurance Services to CD&R and Pincus—yes, Warburg Pincus again—for a reported $17 billion, marking the second time this cycle that Warburg has moved into a large broker position while exiting another. McGill's 300-person headcount and specialist focus contrast with USI's 12,000 employees and middle-market orientation, but both trades reflect a structural bet: that Lloyd's-adjacent specialty placement and program underwriting will compound at mid-teens rates as primary carriers retreat from volatile books. EQT's insurance portfolio already includes Arch's legacy run-off and a stake in Hyperion, a managing general agent. McGill adds distribution leverage in the same treaty and facultative flow.

The valuation and the timing matter. Specialty brokers enjoyed a post-hardening revenue surge from 2021 through mid-2023, but organic growth has decelerated as rate increases moderate and some wholesale capacity re-enters. McGill's commission-based model ties revenue directly to premium volume, and aviation placements—a core vertical—have seen capacity tighten after $8 billion in losses across 2017-2022. EQT is paying for a platform that can cross-sell across specialty verticals and layer in binding authority or MGA economics, where the margin is ten points higher than pure brokerage. The fact that Warburg is rotating capital after a sub-five-year hold suggests they harvested the initial growth phase and are letting the next buyer monetize margin expansion.

Allocators should track three developments over the next twelve months. First, whether EQT layers in acquisitions to build out McGill's fronting or program underwriting capability, which would require regulatory approvals in Bermuda or the UK within six to nine months. Second, whether CD&R and Warburg integrate USI and McGill on the back end—both are now in the Warburg portfolio, and shared distribution infrastructure would create margin leverage. Third, whether Hyperion, EQT's MGA platform, begins steering business to McGill's specialty desks, which would telegraph vertical integration. If that flow materializes by mid-2025, it signals EQT is building an end-to-end specialty insurance stack, not just making a broker bet.

The $2 billion entry at this point in the rate cycle is a view that specialization trumps scale as carriers pull back from complex risk. If correct, McGill's revenue growth should re-accelerate as primary capacity exits and the broker captures a larger share of premium flow. If rate momentum stalls and new capacity floods in by 2026, EQT is left holding a high-multiple broker in a flattening cycle. The fact that both deals—USI and McGill—closed the same week suggests sponsors see a six-quarter window before the next rate inflection.